The DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index.
Tools for translation: non-viral materials for therapeutic mRNA delivery
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To maximize translation, the mRNA sequence typically incorporates modified nucleosides, such as pseudouridine, N1-methylpseudouridine or other nucleoside analogues23.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [23]
In the citing paper
“mRNA has shown therapeutic potential in a range of applications, including viral vaccines, protein replacement therapies, cancer immunotherapies, cellular reprogramming and genome editing2,4,7–17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“These lipids can improve nanoparticle properties, such as particle stability, delivery efficacy, tolerability and biodistribution7,14,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“Trapped in endosomes, in which the pH is lower than in the extracellular environment, ionizable lipids are protonated and, therefore, become positively charged, which may promote membrane destabilization and facilitate endosomal escape of the nanoparticles7,11,14”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“To function in vivo, lipid nanoparticle–mRNA formulations need to overcome multiple extracellular and intracellular barriers7,11 (Fig. 3a).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“In addition to cationic or ionizable lipids, lipid nanoparticle–mRNA formulations typically contain other lipid components, such as phospholipids (for example, phosphatidylcholine and phosphatidylethanolamine), cholesterol or polyethylene glycol (PEG)-functionalized lipids (PEG-lipids)7,14,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“The pH-sensitivity of ionizable lipids is beneficial for mRNA delivery in vivo, because neutral lipids have less interactions with the anionic membranes of blood cells and, thus, improve the biocompatibility of lipid nanoparticles7,11,14.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“mRNA normally contains five structural elements, that is, a 5′ cap, a 3′ poly(A) tail, a protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“These elements can be engineered to improve the stability and translational efficiency of mRNA2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“Chemical modifications of specific IVT mRNA nucleotides, such as pseudouridine (ψ) and N1-methylpseudouridine (m1ψ), can reduce innate immune sensing of exogenous mRNA translation2,4,7,182.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“Chromatographic purification can remove double-stranded RNA, an analogue of viral genome, in IVT mRNA preparations, diminishing immune activation and increasing translational efficiency2,4,7,183.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“To address these concerns, the engineering of mRNA molecules (Box 1) and the design of lipid nanoparticles have been optimized2,4,7–17, which has contributed to the rapid development and clinical assessment15,17 of the two COVID-19 mRNA vaccines, mRNA-1273 (NCT04470427)19,20 and BNT162b2 (NCT04368728)21.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“Polymers, such as polyethyleneimine, protamine and polyaspartamide derivatives, are already widely used for mRNA delivery7–17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [7]
In the citing paper
“mRNA functions as the bridge between DNA and proteins in eukaryotic cells.[8, 12, 119]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Polyethylenimine (PEI) is one of the most developed cationic polymers [39], but its toxicity has limited the therapeutic applications.[8, 124]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Compared with protein drugs, mRNA can supplement both cytoplasmic and large transmembranic proteins.[8, 119, 120]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Recently, many biomaterials have been developed for mRNA delivery, including lipids and lipid derived materials, polymers, and many others. [8, 39, 120, 124]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Relative to plasmid DNA (pDNA), mRNA possesses temporary bioactivity and functions outside the nucleus, leading to a more controllable protein expression and avoiding the potential insertion of the genome.[8, 119, 120]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“For many GARDs, the liver is a preferred organ for mRNA-based PRTs because systemically administrated mRNA vehicles are predominantly trapped by the reticuloendothelial system (RES) in the liver.”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“In addition, the interaction between apolipoprotein E (apoE) and biomaterials such as lipid and lipid derived materials facilitates the accumulation in the liver.[8, 18, 34, 39, 59, 120, 121, 124, 164, 165]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
In the citing paper
“Meanwhile, ionizable lipid and lipid derived materials, which acquire positive charges at low pH and become neutral at physiological pH, have been developed for decreasing the toxicity and immunogenicity while retaining the delivery efficiency.[8]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [8]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Boussif, O., Lezoualc’h, F., Zanta, M. A., Djavaheri‐Mergny, M., Scherman, D., DEMENEIX, B. A., & Behr, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,256
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature reviews. Immunology · doi:10.1038/nri1604 · Cited by 3,631
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Knocking down barriers: advances in siRNA delivery
Whitehead, K. A., Langer, R., & Anderson, D. G. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2742 · Cited by 3,115
Self-citationEfficient genome editing in zebrafish using a CRISPR-Cas system
Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J.-R. J., & Joung, J. K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2501 · Cited by 2,937
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Gene transfer into mouse lyoma cells by electroporation in high electric fields.
Neumann, E., Schaefer-Ridder, M., Wang, Y., & HOFSCHNEIDER, P. H. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01257.x · Cited by 2,510
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Huotari, J., & Helenius, A. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.286 · Cited by 2,448
A "Silent" Polymorphism in the MDR 1 Gene Changes Substrate Specificity
Kimchi-Sarfaty, C., Oh, J. M., Kim, I.-W., Sauna, Z. E., Calcagno, A. M., Ambudkar, S. V., & Gottesman, M. M. (2007) · Science · doi:10.1126/science.1135308 · Cited by 2,416
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Nanoparticle PEGylation for Imaging and Therapy
Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,113
AU-rich elements: characterization and importance in mRNA degradation
Chen, C.-Y. A., & Shyu, A.-B. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89102-1 · Cited by 1,948
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Immune Signaling by RIG-I-like Receptors
Loo, Y.-M., & Gale, M. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.003 · Cited by 1,875
RNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Crick, F. (1958) · PubMed · Cited by 1,487
High-velocity microprojectiles for delivering nucleic acids into living cells
Klein, T. M., Wolf, E. D., Wu, R., & Sanford, J. C. (1987) · Nature · doi:10.1038/327070a0 · Cited by 1,396
Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy
Bonne, G., di Barletta, M. R., Varnous, S., Bécane, H. M., Hammouda, E.-H., Merlini, L., Muntoni, F., Greenberg, C. R., Gary, F., Urtizberea, J. A., et al. (1999) · Nature Genetics · doi:10.1038/6799 · Cited by 1,384
Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis
Akinc, A., Thomas, M., Klibanov, A. M., & Langer, R. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.696 · Cited by 1,339
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
An Unstable Intermediate Carrying Information from Genes to Ribosomes for Protein Synthesis
Brenner, S., Jacob, F., & Meselson, M. S. (1961) · Nature · doi:10.1038/190576a0 · Cited by 1,235
The Many Pathways of RNA Degradation
Houseley, J. M., & Tollervey, D. W. (2009) · Cell · doi:10.1016/j.cell.2009.01.019 · Cited by 1,220
Shatkin, A. J. (1976) · Cell · doi:10.1016/0092-8674(76)90128-8 · Cited by 1,180
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Polyethylenimine-based non-viral gene delivery systems
Lungwitz, U., Breunig, M., Blunk, T., & Göpferich, A. M. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.11.011 · Cited by 998
Untranslated regions of mRNAs.
(2002) · Genome biology · doi:10.1186/gb-2002-3-3-reviews0004 · Cited by 987
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
Ren, J., Liu, X., Fang, C., Jiang, S., June, C. H., & Zhao, Y. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1300 · Cited by 942
Khoury, G. A., Baliban, R. C., & Floudas, C. A. (2011) · Scientific Reports · doi:10.1038/srep00090 · Cited by 936
Complete sequencing and characterization of 21,243 full-length human cDNAs
Ota, T., Suzuki, Y., Nishikawa, T., Otsuki, T., Sugiyama, T., Irie, R., Wakamatsu, A., Hayashi, K., Sato, H., Nagai, K., et al. (2004) · Nature Genetics · doi:10.1038/ng1285 · Cited by 925
Cationic liposome-mediated RNA transfection.
Malone, R. W., Felgner, P. L., & Verma, I. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.16.6077 · Cited by 911
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
Heritable targeted gene disruption in zebrafish using designed zinc-finger nucleases
Doyon, Y., McCammon, J. M., Miller, J. C., Faraji, F., Ngo, C., Katibah, G. E., Amora, R., Hocking, T. D., Zhang, L., Rebar, E. J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1409 · Cited by 896
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Yin, H., Song, C.-Q., Dorkin, J. R., Zhu, L. J., Li, Y., Wu, Q., Park, A., Yang, J., Suresh, S., Bizhanova, A., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3471 · Cited by 876
Gene Therapy for Human Genetic Disease?
Friedmann, T., & Roblin, R. O. (1972) · Science · doi:10.1126/science.175.4025.949 · Cited by 819
Kauffman, K. J., Dorkin, J. R., Yang, J. H., Heartlein, M. W., DeRosa, F., Mir, F. F., Fenton, O. S., & Anderson, D. G. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b02497 · Cited by 796
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Regulation of mRNA stability in mammalian cells
Guhaniyogi, J., & Brewer, G. (2001) · Gene · doi:10.1016/s0378-1119(01)00350-x · Cited by 729
Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy
Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., Anderson, D. G., Langer, R., & Blankschtein, D. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b03329 · Cited by 719
The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery
Cheng, X., & Lee, R. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.022 · Cited by 703
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701
Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown
Wittrup, A., Ai, A., Liu, X., Hamar, P., Trifonova, R., Charisse, K., Manoharan, M., Kirchhausen, T., & Lieberman, J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3298 · Cited by 693
Targeted Genome Editing Across Species Using ZFNs and TALENs
Wood, A. J., Lo, T., Zeitler, B., Pickle, C. S., Ralston, E. J., Lee, A. H., Amora, R., Miller, J. C., Leung, E., Meng, X., et al. (2011) · Science · doi:10.1126/science.1207773 · Cited by 682
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq347 · Cited by 682
Lipid-based Nanoparticles for Nucleic Acid Delivery
Li, W., & Szoka, F. C. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9180-5 · Cited by 660
Progress and prospects: immune responses to viral vectors
Nayak, S., & Herzog, R. W. (2009) · Gene Therapy · doi:10.1038/gt.2009.148 · Cited by 647
Zangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2682 · Cited by 646
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Mechanism of oligonucleotide release from cationic liposomes.
Zelphati, O., & Szoka, F. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11493 · Cited by 634
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 627
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622
Design of biodegradable particles for protein delivery
Vila, A., Sánchez, A., Tobío, M. T. B., Calvo, P., & Alonso, M. J. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00486-2 · Cited by 620
Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity
Whitehead, K. A., Dorkin, J. R., Vegas, A. J., Chang, P. H., Veiseh, O., Matthews, J., Fenton, O. S., Zhang, Y., Olejnik, K. T., Yesilyurt, V., et al. (2014) · Nature Communications · doi:10.1038/ncomms5277 · Cited by 615
Self-citationOn the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids
Hafez, I., Maurer, N., & Cullis, P. R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301506 · Cited by 601
Sharova, L. V., Sharov, A. A., Nedorezov, T., Piao, Y., Shaik, N., & Ko, M. S. H. (2009) · DNA Research · doi:10.1093/dnares/dsn030 · Cited by 591
A MULTIPLE RIBOSOMAL STRUCTURE IN PROTEIN SYNTHESIS
Warner, J. R., Knopf, P. M., & Rich, A. (1963) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.49.1.122 · Cited by 583
Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M. A., Lallas, C. D., Dahm, P., Niedzwiecki, D., Gilboa, E., & Vieweg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214364 · Cited by 562
Miller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., Zhu, H., & Siegwart, D. J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610209 · Cited by 540
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 513
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
Kalos, M. D., & June, C. H. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.002 · Cited by 501
The origins and functions of dendritic cells and macrophages in the skin
MALISSEN, B., Tamoutounour, S., & Henri, S. (2014) · Nature reviews. Immunology · doi:10.1038/nri3683 · Cited by 484
Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA
Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E., Guillet, J., Lévy, J., & Meulien, P. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230749 · Cited by 473
Van Tendeloo, V. F. I., Ponsaerts, P., Lardon, F., Nijs, G., Lenjou, M., Van Broeckhoven, C., Van Bockstaele, D. R., & Berneman, Z. N. (2001) · Blood · doi:10.1182/blood.v98.1.49 · Cited by 468
Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 464
TAIL-seq: Genome-wide Determination of Poly(A) Tail Length and 3′ End Modifications
Chang, H., Lim, J., Ha, M., & Kim, V. N. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.02.007 · Cited by 454
siRNA Delivery Strategies: A Comprehensive Review of Recent Developments
Tatiparti, K., Sau, S., Kashaw, S. K., & Iyer, A. K. (2017) · Nanomaterials · doi:10.3390/nano7040077 · Cited by 444
Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414
Epigenetic mechanisms in neurogenesis
Yao, B., Christian, K. M., He, C., Jin, P., Ming, G., & Song, H. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.70 · Cited by 406
CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
Liu, X., Zhang, Y., Cheng, C., Cheng, A. W., Zhang, X., Li, N., Xia, C., Wei, X., Liu, X., & Wang, H. (2016) · Cell Research · doi:10.1038/cr.2016.142 · Cited by 401
Hegde, M. G., Corder, A., Chow, K. K. H., Mukherjee, M., Ashoori, A., Kew, Y., Zhang, Y. J., Baskin, D. S., Merchant, F. A., Brawley, V. S., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.185 · Cited by 370
A Role for Codon Order in Translation Dynamics
Cannarozzi, G., Schraudolph, N. N., Faty, M., von Rohr, P., Friberg, M. T., Roth, A. C., Gonnet, P., Gonnet, G., & Barral, Y. (2010) · Cell · doi:10.1016/j.cell.2010.02.036 · Cited by 354
Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352
Nair, S. K., Heiser, A., Boczkowski, D., Majumdar, A. S., Naoe, M., LEBKOWSKI, J. S., Vieweg, J., & Gilboa, E. (2000) · Nature Medicine · doi:10.1038/79519 · Cited by 348
Polymer–Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs
Kaczmarek, J. C., Patel, A. K., Kauffman, K. J., Fenton, O. S., Webber, M. J., Heartlein, M. W., DeRosa, F., & Anderson, D. G. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608450 · Cited by 337
(1995) · PubMed · Cited by 330
Hashimoto, M., & Takemoto, T. (2015) · Scientific Reports · doi:10.1038/srep11315 · Cited by 326
Virus-mediated gene delivery for human gene therapy
Giacca, M., & Zacchigna, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.008 · Cited by 302
Systemic delivery of factor IX messenger RNA for protein replacement therapy
Ramaswamy, S., Tonnu, N., Tachikawa, K., Limphong, P., Vega, J. B., Karmali, P. P., Chivukula, P., & Verma, I. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619653114 · Cited by 301
A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo
Jiang, C., Mei, M., Li, B., Zhu, X., Zu, W., Tian, Y., Wang, Q., Guo, Y., Dong, Y., & Tan, X. (2017) · Cell Research · doi:10.1038/cr.2017.16 · Cited by 295
McKinlay, C. J., Vargas, J. R., Blake, T. R., Hardy, J. W., Kanada, M., Contag, C. H., Wender, P. A., & Waymouth, R. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614193114 · Cited by 288
Langlet, C., Tamoutounour, S., Henri, S., Luche, H., Ardouin, L., Grégoire, C., MALISSEN, B., & Guilliams, M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102744 · Cited by 284
Karikó, K., Muramatsu, H., Keller, J. M., & Weissman, D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.7 · Cited by 282
Reversal of Diabetes Insipidus in Brattleboro Rats: Intrahypothalamic Injection of Vasopressin mRNA
Jirikowski, G. F., Sanna, P. P., Maciejewski-Lenoir, D., & Bloom, F. E. (1992) · Science · doi:10.1126/science.1546298 · Cited by 282
The major mRNA‐associated protein YB‐1 is a potent 5′ cap‐dependent mRNA stabilizer
Evdokimova, V. E., Ruzanov, P., Imataka, H., Raught, B., Svitkin, Y. V., Ovchinnikov, L. P., & Sonenberg, N. (2001) · The EMBO Journal · doi:10.1093/emboj/20.19.5491 · Cited by 280
Wang, T., Upponi, J. R., & Torchilin, V. P. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.013 · Cited by 272
Lockard, R. E., & Lingrel, J. B. (1969) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(69)90720-7 · Cited by 269
An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo
Li, B., Luo, X., Deng, B., Wang, J., McComb, D. W., Shi, Y., Gaensler, K. M. L., Tan, X., Dunn, A. L., Kerlin, B. A., et al. (2015) · Nano Letters · doi:10.1021/acs.nanolett.5b03528 · Cited by 261
Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery
Fenton, O. S., Kauffman, K. J., McClellan, R. L., Appel, E. A., Dorkin, J. R., Tibbitt, M. W., Heartlein, M. W., DeRosa, F., Langer, R., & Anderson, D. G. (2016) · Advanced Materials · doi:10.1002/adma.201505822 · Cited by 252
eIF4G Dramatically Enhances the Binding of eIF4E to the mRNA 5′-Cap Structure
Haghighat, A., & Sonenberg, N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.21677 · Cited by 239
Perche, F., Benvegnu, T. J., Berchel, M., Lebegue, L., Pichon, C., Jaffrès, P., & Midoux, P. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2010.12.010 · Cited by 228
Cationic lipids enhance siRNA-mediated interferon response in mice
Ma, Z., Li, J., He, F., Wilson, A. S., Pitt, B. R., & Li, S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.041 · Cited by 227
Treatment of Advanced Leukemia in Mice with mRNA Engineered T Cells
Barrett, D. M., Zhao, Y., Liu, X., Jiang, S., Carpenito, C., Kalos, M. D., Carroll, R. G., June, C. H., & Grupp, S. A. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.070 · Cited by 224
Reprogramming human fibroblasts to pluripotency using modified mRNA
Mandal, P., & Rossi, D. J. (2013) · Nature Protocols · doi:10.1038/nprot.2013.019 · Cited by 219
Trafficking of endosomal Toll-like receptors
Lee, B. L., & Barton, G. M. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.12.002 · Cited by 214
Lipid-based mRNA vaccine delivery systems
Midoux, P., & Pichon, C. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.986104 · Cited by 213
Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes
DIMITRIADIS, G. J. (1978) · Nature · doi:10.1038/274923a0 · Cited by 212
Li, M., Zhao, M., Fu, Y., Li, Y., Gong, T., Zhang, Z., & Sun, X. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.043 · Cited by 201
Protein Glycosylation: New Challenges and Opportunities
Wong, C. (2005) · The Journal of Organic Chemistry · doi:10.1021/jo050278f · Cited by 192
Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines
Deering, R. P., Kommareddy, S., Ulmer, J. B., Brito, L. A., & Geall, A. J. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.901308 · Cited by 180
Generation of knockout mice by Cpf1-mediated gene targeting
Kim, Y., Cheong, S.-A., Lee, J. G., Lee, S.-W., Lee, M. S., Baek, I., & Sung, Y. H. (2016) · Nature Biotechnology · doi:10.1038/nbt.3614 · Cited by 171
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system
DeRosa, F., Guild, B., Karve, S., Smith, L., Love, K., Dorkin, J. R., Kauffman, K. J., Zhang, J., Yahalom, B., Anderson, D. G., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.46 · Cited by 159
Functional expression of chimeric receptor genes in human T cells
Eshhar, Z., Waks, T., Bendavid, A., & Schindler, D. G. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00343-4 · Cited by 158
Lorenz, C., Fotin‐Mleczek, M., Roth, G. D., Becker, C., Dam, T. C., Verdurmen, W. P. R., Brock, R. E., Probst, J., & Schlake, T. (2011) · RNA Biology · doi:10.4161/rna.8.4.15394 · Cited by 152
Uchida, S., Kinoh, H., Ishii, T., Matsui, A., Tockary, T. A., Takeda, K. M., Uchida, H., Osada, K., Itaka, K., & Kataoka, K. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.031 · Cited by 151
Qiu, P., Ziegelhoffer, P. R., Sun, J., & Yang, N. S. (1996) · PubMed · Cited by 150
In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency
Mahiny, A. J., Dewerth, A., Mays, L. E., Alkhaled, M., Mothes, B., Malaeksefat, E., Loretz, B., Rottenberger, J., Brosch, D. M., Reautschnig, P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3241 · Cited by 139
RNA Melanoma Vaccine: Induction of Antitumor Immunity by Human Glycoprotein 100 mRNA Immunization
Zhou, W.-Z., Hoon, D. S. �., Huang, S., Fujii, S., Hashimoto, K., Morishita, R., & Kaneda, Y. (1999) · Human Gene Therapy · doi:10.1089/10430349950016762 · Cited by 136
mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers
Rejman, J., Tavernier, G., Bavarsad, N., Demeester, J., & Smedt, S. C. D. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.07.124 · Cited by 133
Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA
Zhao, M., Li, M., Zhang, Z., Gong, T., & Sun, X. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1038856 · Cited by 132
Karikó, K., & Weissman, D. (2007) · PubMed · Cited by 130
In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model
Mandl, C. W., Aberle, J. H., Aberle, S. W., Holzmann, H., Allison, S. L., & Heinz, F. X. (1998) · Nature Medicine · doi:10.1038/4031 · Cited by 124
Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours
Zámečnı́k, J., Vargová, L., Homola, A., Kodet, R., & Syková, E. (2004) · Neuropathology and Applied Neurobiology · doi:10.1046/j.0305-1846.2003.00541.x · Cited by 123
Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., Verbeke, R., Lentacker, I., Thielemans, K., & Breckpot, K. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.38 · Cited by 121
Single-cell mRNA transfection studies: Delivery, kinetics and statistics by numbers
Leonhardt, C., Schwake, G., Stögbauer, T. R., Rappl, S., Kuhr, J.-T., Ligon, T. S., & Rädler, J. O. (2014) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2013.11.008 · Cited by 117
Choi, H. Y., Lee, T., Yang, G., Oh, J., Won, J., Han, J., Jeong, G., Kim, J., Kim, J., Kim, B., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.007 · Cited by 114
Barrett, D. M., Liu, X., Jiang, S., June, C. H., Grupp, S. A., & Zhao, Y. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.075 · Cited by 113
Lin, C., Perche, F., Ikegami, M., Uchida, S., Kataoka, K., & Itaka, K. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.001 · Cited by 113
Aini, H., Itaka, K., Fujisawa, A., Uchida, H., Uchida, S., Fukushima, S., Kataoka, K., Saito, T., Chung, U., & Ohba, S. (2016) · Scientific Reports · doi:10.1038/srep18743 · Cited by 112
Poly(glycoamidoamine) Brushes Formulated Nanomaterials for Systemic siRNA and mRNA Delivery in Vivo
Dong, Y., Dorkin, J. R., Wang, W., Chang, P., Webber, M. J., Tang, B. C., Yang, J., Ionita, I. A., Danino, D., DeRosa, F., et al. (2016) · Nano Letters · doi:10.1021/acs.nanolett.5b02428 · Cited by 111
Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles
Baba, M., Itaka, K., Kondo, K., Yamasoba, T., & Kataoka, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.017 · Cited by 109
Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
Cavazzana, M., Six, E., Lagresle-Peyrou, C., André-Schmutz, I., & Hacein-Bey-Abina, S. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.137 · Cited by 106
Yoon, S. H., Lee, J. M., Cho, H. I., Kim, E. K., Kim, H. S., Park, M. Y., & Kim, T. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.98 · Cited by 102
In Vitro Transcription: Preparative RNA Yields in Analytical Scale Reactions
Pokrovskaya, I. D., & Gurevich, V. V. (1994) · Analytical Biochemistry · doi:10.1006/abio.1994.1360 · Cited by 101
Jarzębińska, A., Pasewald, T., Lambrecht, J., Mykhaylyk, O., Kümmerling, L., Beck, P., Hasenpusch, G., Rudolph, C., Plank, C., & Dohmen, C. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201603648 · Cited by 101
Meijer, H. A., Bushell, M., Hill, K., Gant, T. W., Willis, A. E., Jones, P., & de Moor, C. H. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm830 · Cited by 98
Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases
Matsui, A., Uchida, S., Ishii, T., Itaka, K., & Kataoka, K. (2015) · Scientific Reports · doi:10.1038/srep15810 · Cited by 93
A Targeted and Stable Polymeric Nanoformulation Enhances Systemic Delivery of mRNA to Tumors
Chen, Q., Qi, R., Chen, X., Yang, X., Wu, S., Xiao, H., & Dong, W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.006 · Cited by 91
Karikó, K., Kuo, A., & Barnathan, E. S. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300930 · Cited by 89
Characterization of Lipid DNA Interactions. I. Destabilization of Bound Lipids and DNA Dissociation
Harvie, P., Wong, F. M. P., & Bally, M. B. (1998) · Biophysical Journal · doi:10.1016/s0006-3495(98)77593-9 · Cited by 86
Immunize and disappear—Safety-optimized mRNA vaccination with a panel of 29 allergens
Roesler, E., Weiss, R., Weinberger, E. E., Fruehwirth, A., Stoecklinger, A., Mostböck, S., Ferreira, F., Thalhamer, J., & Scheiblhofer, S. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.06.036 · Cited by 82
Structurally Programmed Assembly of Translation Initiation Nanoplex for Superior mRNA Delivery
Li, J., Wang, W., He, Y., Li, Y., Yan, E. Z., Zhang, K., Irvine, D. J., & Hammond, P. T. (2017) · ACS Nano · doi:10.1021/acsnano.6b08447 · Cited by 82
Chiper, M., Tounsi, N., Kole, R., Kichler, A., & Zuber, G. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.005 · Cited by 81
Transcript-activated collagen matrix as sustained mRNA delivery system for bone regeneration
Badieyan, Z. S., Berezhanskyy, T., Utzinger, M., Aneja, M. K., Emrich, D., Erben, R. G., Schüler, C., Altpeter, P., Ferizi, M., Hasenpusch, G., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.037 · Cited by 80
RNA-based gene transfer for adult stem cells and T cells
Smits, E., Ponsaerts, P., Lenjou, M., Nijs, G., van Bockstaele, D. V., Berneman, Z., & Tendeloo, V. V. (2004) · Leukemia · doi:10.1038/sj.leu.2403463 · Cited by 67
Anderson, D. M., Hall, L. L., Ayyalapu, A. R., Irion, V. R., Nantz, M. H., & Hecker, J. G. (2003) · Human Gene Therapy · doi:10.1089/10430340360535751 · Cited by 66
Toxicity profiling of several common RNAi-based nanomedicines: a comparative study
Landesman‐Milo, D., & Peer, D. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0158-7 · Cited by 64
Balmayor, E. R., Geiger, J. P., Koch, C., Aneja, M. K., van Griensven, M., Rudolph, C., & Plank, C. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0171 · Cited by 62
Polymer–Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs
Kaczmarek, J. C., Patel, A. K., Kauffman, K. J., Fenton, O. S., Webber, M. J., Heartlein, M. W., DeRosa, F., & Anderson, D. G. (2016) · Angewandte Chemie · doi:10.1002/ange.201608450 · Cited by 60
Synthesis, Characterization, and Evaluation of Ionizable Lysine-Based Lipids for siRNA Delivery
Walsh, C. L., Nguyen, J., Tiffany, M. R., & Szoka, F. C. (2012) · Bioconjugate Chemistry · doi:10.1021/bc300346h · Cited by 51
Site-specific gene delivery in vivo through engineered Sendai viral envelopes
Ramani, K., Hassan, Q., Betapudi, V., Hasnain, S. E., & Sarkar, D. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11886 · Cited by 50
The hemophilias and their clinical management
Josephson, N. C. (2013) · Hematology · doi:10.1182/asheducation-2013.1.261 · Cited by 32
Dual-functional lipid-like nanoparticles for delivery of mRNA and MRI contrast agents
Luo, X. L., Li, B., Zhang, X., Zhao, W., Bratasz, A., Deng, B., McComb, D. W., & Dong, Y. (2016) · Nanoscale · doi:10.1039/c6nr08496f · Cited by 30
Hattinger, E., Scheiblhofer, S., Roesler, E., Thalhamer, T., Thalhamer, J., & Weiss, R. (2015) · Journal of Immunology Research · doi:10.1155/2015/797421 · Cited by 29
Microinjection of mRNA into Somatic Cells
Murata‐Hori, M., & Wang, Y. (2005) · Encyclopedia of Life Sciences · doi:10.1038/npg.els.0002696 · Cited by 3
Endocrinological Problems in Agriculture
Rowlands, I. W. (1957) · Nature · doi:10.1038/180576a0 · Cited by 2
Research works printed but not linked: 1
- Moderna Therapeutics. Moderna Provides Pipeline and Full-Year Corporate Update. Moderna [online], https://www.modernatx.com/newsroom/press-releases/moderna-provides-pipeline-and-full-year-corporate-update (2017).
Cited by
Sorted by citations
Lipid nanoparticles for mRNA delivery
Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00358-0 · Cited by 4,076
Delivery technologies for cancer immunotherapy
Riley, R., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,678
“Part a is adapted from ref.(150), Springer Nature”
Cheng, Q., Wei, T., Farbiak, L., Johnson, L. T., Dilliard, S. A., & Siegwart, D. J. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0669-6 · Cited by 2,383
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Self-citationDelivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
“Intratumoral mRNA vaccination is also being investigated, since it may offer the advantage of rapid and specific activation of tumor-resident T cells.(1,189)”
Metadata
- Authors
- Hajj, K. A., & Whitehead, K. A.
- Affiliations
- Carnegie Mellon University (US)
- Corresponding author
- Whitehead, Kathryn A.
- Venue
- Nature Reviews Materials
- Published
- 2017-09-12
- Volume
- 2
- Issue
- 10
- ISSN
- 2058-8437 (ISSN-L)
- OpenAlex
- W2754401101
- Cited by
- 799
- References
- 166
- Citations by year
- 2026: 61 · 2025: 122 · 2024: 110 · 2023: 126 · 2022: 124 · 2021: 101 · 2020: 82 · 2019: 40 · 2018: 32 · 2017: 1
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Reviews Materials (publishedVersion)
- Funders
- Defense Advanced Research Projects Agency (D16AP00143)
- Advanced Research Projects Agency
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- mRNA therapeutics, mRNA delivery, synthetic materials, lipid nanoparticles, mRNA vaccines, cancer immunotherapy, in vitro transcribed mRNA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
